Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
Braz. J. Pharm. Sci. (Online)
; 53(1): e16102, 2017. tab, graf
Article
en En
| LILACS, SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-839466
Biblioteca responsable:
BR1.1
ABSTRACT
ABSTRACT Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Ansiedad
/
Colesterol
/
Simvastatina
Tipo de estudio:
Systematic_reviews
Límite:
Animals
Idioma:
En
Revista:
Braz. J. Pharm. Sci. (Online)
Asunto de la revista:
Farmacologia
/
Teraputica
/
Toxicologia
Año:
2017
Tipo del documento:
Article